Statement: There were more cases of Anemia and Leukopenia in the primary trial than the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 29/48 (60.42%)   Anemia 4/48 (8.33%)   Febrile neutropenia 7/48 (14.58%)   Atrial fibrillation 1/48 (2.08%)   Pericardial effusion 1/48 (2.08%)   Sinus bradycardia 1/48 (2.08%)   Nausea 2/48 (4.17%)   Vomiting 2/48 (4.17%)   Death NOS 1/48 (2.08%)   Fatigue 3/48 (6.25%)   Allergic reaction 1/48 (2.08%)   Lung infection 1/48 (2.08%)   Mucosal infection 1/48 (2.08%)
Secondary_evidence: Adverse Events 1:   Total: 28/39 (71.79%)   Anemia 1/39 (2.56%)   Leukopenia 4/39 (10.26%)   Neutropenia 4/39 (10.26%)   Chest Pain 1/39 (2.56%)   Pericarditis 1/39 (2.56%)   Sinus Tach. 1/39 (2.56%)   Sinus Tachycardia 1/39 (2.56%)   Eye tearing 1/39 (2.56%)   Diarrhea 7/39 (17.95%)   Mucositis 3/39 (7.69%)   Nausea 2/39 (5.13%)   Vomiting  [1]1/39 (2.56%)   Fatigue 6/39 (15.38%)